Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia (Q39468003)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 September 2011

Language	Label	Description	Also known as
English	Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia	scientific article published on 23 September 2011

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia (English)

1 reference

Europe PubMed Central

12 September 2017

1 reference

based on heuristic

inferred from title

author name string

Kazutaka Takagi

1

1 reference

Europe PubMed Central

12 September 2017

Yasukazu Kawai

2

1 reference

Europe PubMed Central

12 September 2017

Takahiro Yamauchi

3

1 reference

Europe PubMed Central

12 September 2017

Hiromichi Iwasaki

4

1 reference

Europe PubMed Central

12 September 2017

Takanori Ueda

5

1 reference

Europe PubMed Central

12 September 2017

publication date

23 September 2011

1 reference

Europe PubMed Central

12 September 2017

International Journal of Hematology

1 reference

Europe PubMed Central

12 September 2017

94

1 reference

Europe PubMed Central

12 September 2017

4

1 reference

Europe PubMed Central

12 September 2017

378-389

1 reference

Europe PubMed Central

12 September 2017

https://scigraph.springernature.com/pub.10.1007/s12185-011-0930-8

0 references

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Enhanced DNA excision repair in CCRF-CEM cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea, quantitated using the single cell gel electrophoresis (Comet) assay

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Cellular and clinical pharmacology of fludarabine

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

A simple technique for quantitation of low levels of DNA damage in individual cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Histone H2A variants H2AX and H2AZ

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Topoisomerase I inhibitors: camptothecins and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0930-8

21 January 2018

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Development of carboplatin]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA excision repair profiles of normal and leukemic human lymphocytes: functional analysis at the single-cell level

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21948264

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-011-0930-8

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39468003&oldid=1829678889"